ESYT1

Across TCGA pan-cancer cohorts, ESYT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ESYT1 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ESYT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ESYT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, OV, and PDAC are the cancer types where ESYT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.221	0.978	.024	12	view →
OV	DFS	Median	All	0.871	1.000	.048	4	view →
PDAC	OS	Quartile	All	0.719	0.483	.028	4	view →
GBM	OS	Tertile	All	0.310	0.644	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ESYT1–CCRCC (DFS)

Open the CCRCC breakdown →